This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XBiotech Announces Results For Its XILONIX™ Treatment Of Non-Small Cell Lung Cancer (NSCLC)

AUSTIN, Texas, May 15, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today its recent findings for Non-Small Cell Lung Cancer (NSCLC). Sixteen advanced NSCLC patients were treated at MD Anderson Cancer Center with the Company's True Human Therapeutic Antibody XILONIX™. The patients receiving XILONIX had failed all conventional therapy and had progressive disease upon receiving treatment with XILONIX. Over half of the patients treated recovered significant amounts of lean body tissue during treatment; as well, these patients showed a trend toward improved overall physical and functional well-being. A key outcome, however, was the observation that patient overall survival outcomes appeared significantly better than what would be expected for this late stage NSCLC patient population. Stratification of survival outcomes based on patient pretreatment history also provided some interesting findings. Sixty-three percent of the NSCLC patients treated in the study had actually received—and failed—previous treatment regimens with the anti-cancer agent Tarceva™. Surprisingly, these patients appeared to have considerably better survival outcomes than patients with other pre-treatment histories.

Dr. Michael Stecher, XBiotech's Medical Director, says, "We are very encouraged with the response to therapy seen in advanced NSCLC patients. Again we see that XILONIX treatment is associated with recovery from disease, and life extension."

ABOUT XBIOTECHXBiotech was founded in 2005 to commercialize next generation antibody therapeutics. Results to date show a promising treatment for late stage cancer. The Company's lead product candidate, a novel, breakthrough anti-inflammatory, is now in Phase III clinical studies for the treatment of advanced colorectal cancer. The same anti-inflammatory therapeutic has been used by the Company in clinical studies to treat acne, psoriasis, type 2 diabetes and cardiovascular disease. Results suggest that this single agent may be useful in treating multiple disease indications. XBiotech believes that this extraordinary lead product represents what is perhaps the greatest single-product value potential in the therapeutic antibody space.

XBiotech also has a discovery platform for True Human™ therapeutic antibodies, for which several candidates are in the pre-clinical pipeline. As part of its commercialization strategy, XBiotech has advanced disposable bioreactor manufacturing technology to reduce infrastructure needs, lessen capital requirements and lead times. Low-complexity production capability suggests a new paradigm of cost and development efficiency in the biopharmaceutical space.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs